Insider Trading Alert - GBNK, VVI And PTX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 6, 2015, 74 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $199.44 to $8,899,995.42.

Highlighted Stocks Traded by Insiders:

Guaranty Bancorp (GBNK) - FREE Research Report

DiPetro Michael J, who is EVP, Retail Banking Manager at Guaranty Bancorp, sold 689 shares at $16.09 on May 6, 2015. Following this transaction, the EVP, Retail Banking Manager owned 14,010 shares meaning that the stake was reduced by 4.69% with the 689-share transaction.

The shares most recently traded at $16.13, up $0.04, or 0.25% since the insider transaction. Historical insider transactions for Guaranty Bancorp go as follows:

  • 4-Week # shares bought: 20
  • 4-Week # shares sold: 2,909
  • 12-Week # shares bought: 20
  • 12-Week # shares sold: 2,909
  • 24-Week # shares bought: 20
  • 24-Week # shares sold: 2,909

The average volume for Guaranty Bancorp has been 112,800 shares per day over the past 30 days. Guaranty Bancorp has a market cap of $331.1 million and is part of the financial sector and banking industry. Shares are up 10.66% year-to-date as of the close of trading on Wednesday.

Guaranty Bancorp operates as the bank holding company for Guaranty Bank and Trust Company that provides various banking products and services to consumers, and small to medium-sized businesses. The stock currently has a dividend yield of 2.5%. The company has a P/E ratio of 25.0. Currently, there is 1 analyst who rates Guaranty Bancorp a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GBNK - FREE

TheStreet Quant Ratings rates Guaranty Bancorp as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, increase in net income, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Guaranty Bancorp Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Viad (VVI) - FREE Research Report

Schechter Joshua, who is Director at Viad, bought 2,000 shares at $26.79 on May 6, 2015. Following this transaction, the Director owned 15,726 shares meaning that the stake was boosted by 14.57% with the 2,000-share transaction.

Dozer Richard H, who is Director at Viad, sold 2,335 shares at $26.39 on May 6, 2015. Following this transaction, the Director owned 20,222 shares meaning that the stake was reduced by 10.35% with the 2,335-share transaction.

The shares most recently traded at $27.22, up $0.83, or 3.03% since the insider transaction. Historical insider transactions for Viad go as follows:

  • 4-Week # shares sold: 4,000
  • 12-Week # shares sold: 4,000
  • 24-Week # shares sold: 4,000

The average volume for Viad has been 104,100 shares per day over the past 30 days. Viad has a market cap of $532.0 million and is part of the services sector and diversified services industry. Shares are down 0.38% year-to-date as of the close of trading on Wednesday.

Viad Corp provides experiential services in the exhibition and events, and travel and recreation industries in the United States, Canada, the United Kingdom, Germany, and the United Arab Emirates. The stock currently has a dividend yield of 1.51%. The company has a P/E ratio of 10.2. Currently, there are no analysts who rate Viad a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on VVI - FREE

TheStreet Quant Ratings rates Viad as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Viad Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pernix Therapeutics Holdings (PTX) - FREE Research Report

Drysdale Douglas, who is Chief Executive Officer at Pernix Therapeutics Holdings, bought 16,000 shares at $6.40 on May 6, 2015. Following this transaction, the Chief Executive Officer owned 96,661 shares meaning that the stake was boosted by 19.84% with the 16,000-share transaction.

Patel Sanjay S, who is Chief Financial Officer at Pernix Therapeutics Holdings, bought 2,000 shares at $6.42 on May 6, 2015. Following this transaction, the Chief Financial Officer owned 2,000 shares meaning that the stake was boosted by 100% with the 2,000-share transaction.

The shares most recently traded at $6.79, up $0.37, or 5.45% since the insider transaction. Historical insider transactions for Pernix Therapeutics Holdings go as follows:

  • 4-Week # shares sold: 14,400
  • 12-Week # shares sold: 14,400
  • 24-Week # shares sold: 14,400

The average volume for Pernix Therapeutics Holdings has been 1.1 million shares per day over the past 30 days. Pernix Therapeutics Holdings has a market cap of $277.8 million and is part of the health care sector and drugs industry. Shares are down 32.06% year-to-date as of the close of trading on Wednesday.

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells branded and generic pharmaceutical products. Currently, there are 4 analysts who rate Pernix Therapeutics Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on PTX - FREE

TheStreet Quant Ratings rates Pernix Therapeutics Holdings as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity and feeble growth in its earnings per share. Get the full Pernix Therapeutics Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%